These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 8468725

  • 1. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
    Zaharevitz DW, Grubb MF, Hyman R, Chisena C, Cysyk RL.
    J Natl Cancer Inst; 1993 Apr 21; 85(8):662-6. PubMed ID: 8468725
    [Abstract] [Full Text] [Related]

  • 2. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A, Anderson LW, Strong J, Cysyk RL.
    J Biol Chem; 1983 Nov 25; 258(22):13564-9. PubMed ID: 6417130
    [Abstract] [Full Text] [Related]

  • 3. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
    Kensler TW, Jayaram HN, Cooney DA.
    Adv Enzyme Regul; 1982 Nov 25; 20():57-73. PubMed ID: 7113804
    [Abstract] [Full Text] [Related]

  • 4. Contribution of de-novo and salvage synthesis to the uracil nucleotide pool in mouse tissues and tumors in vivo.
    Zaharevitz DW, Anderson LW, Malinowski NM, Hyman R, Strong JM, Cysyk RL.
    Eur J Biochem; 1992 Nov 15; 210(1):293-6. PubMed ID: 1446677
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C, Vidgen D.
    Biochem Pharmacol; 1984 Oct 15; 33(20):3177-81. PubMed ID: 6487365
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW, Mutter G, Hankerson JG, Reck LJ, Harley C, Han N, Ardalan B, Cysyk RL, Johnson RK, Jayaram HN, Cooney DA.
    Cancer Res; 1981 Mar 15; 41(3):894-904. PubMed ID: 7459875
    [Abstract] [Full Text] [Related]

  • 7. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC.
    Biochem Pharmacol; 1982 Oct 15; 31(20):3313-6. PubMed ID: 7150357
    [Abstract] [Full Text] [Related]

  • 8. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
    Peters GJ.
    Nucleosides Nucleotides Nucleic Acids; 2018 Oct 15; 37(6):329-339. PubMed ID: 29723133
    [Abstract] [Full Text] [Related]

  • 9. The role of low-dose PALA in biochemical modulation.
    O'Dwyer PJ.
    Pharmacol Ther; 1990 Oct 15; 48(3):371-80. PubMed ID: 2084707
    [Abstract] [Full Text] [Related]

  • 10. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
    Karle JM, Cowan KH, Chisena CA, Cysyk RL.
    Mol Pharmacol; 1986 Aug 15; 30(2):136-41. PubMed ID: 2874477
    [Abstract] [Full Text] [Related]

  • 11. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    Yang JL, Fernandes DJ, Wheeler KT, Capizzi RL.
    Int J Radiat Oncol Biol Phys; 1996 Mar 15; 34(5):1073-9. PubMed ID: 8600090
    [Abstract] [Full Text] [Related]

  • 12. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
    Karle JM, Anderson LW, Dietrick DD, Cysyk RL.
    Cancer Res; 1981 Dec 15; 41(12 Pt 1):4952-5. PubMed ID: 6171344
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
    Miller AA, Moore EC, Hurlbert RB, Benvenuto JA, Loo TL.
    Cancer Res; 1983 Jun 15; 43(6):2565-70. PubMed ID: 6189583
    [Abstract] [Full Text] [Related]

  • 15. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B, Jayaram HN, Johnson RK.
    Cancer Res; 1983 Apr 15; 43(4):1598-601. PubMed ID: 6831405
    [Abstract] [Full Text] [Related]

  • 16. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C.
    Recent Results Cancer Res; 1980 Apr 15; 74():65-71. PubMed ID: 7444150
    [Abstract] [Full Text] [Related]

  • 17. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
    Jacobsen LB, Putnam JE, Sawick DP, Cassady JM, Morré DJ.
    Life Sci; 1988 Apr 15; 42(8):913-8. PubMed ID: 3343891
    [Abstract] [Full Text] [Related]

  • 18. Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
    Martin DS, Kemeny NE.
    Semin Oncol; 1992 Apr 15; 19(2 Suppl 3):49-55. PubMed ID: 1557657
    [Abstract] [Full Text] [Related]

  • 19. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES, Vale K, Williams LJ, Martin DS, Young CW.
    Cancer Res; 1983 May 15; 43(5):2324-9. PubMed ID: 6831457
    [Abstract] [Full Text] [Related]

  • 20. Mechanism-based model for tumor drug resistance.
    Kuczek T, Chan TC.
    Cancer Chemother Pharmacol; 1992 May 15; 30(5):355-9. PubMed ID: 1505073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.